Mazisotine - Eli Lilly and Company
Alternative Names: CNTX-0290; LY-3556050Latest Information Update: 03 Jun 2025
At a glance
- Originator Boehringer Ingelheim
- Developer Centrexion Therapeutics; Eli Lilly and Company
- Class Amides; Amines; Anti-inflammatories; Aza compounds; Ethers; Heterocyclic bicyclo compounds; Non-opioid analgesics; Pyridines; Small molecules
- Mechanism of Action Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Back pain; Neuropathic pain; Pain
Most Recent Events
- 03 Jun 2025 Chemical structure information added
- 05 Aug 2024 Pooled adverse events, pharmacokinetics and efficacy data from a phase II trial in Pain presented at the 20th World Congress on Pain (WCP-2024)
- 05 Aug 2024 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Neuropathic pain presented at the 20th World Congress on Pain (WCP-2024)